Marcus Snow, MD, FACR, had his first exposure to rheumatology in a rotation during his residency at the University of Nebraska Medical Center, Omaha. James O’Dell, MD, Theodore Mikuls, MD, Jay Moore, MD, Lynn Klassen, MD, and other physicians showed how rheumatology could be the perfect mix of a narrow clinical focus with interesting patient…
Through the development of a multidisciplinary musculoskeletal institute, we have created a model that facilitates coordination of care of complex patients between medical and surgical subspecialists, physical therapists, dieticians and social workers. A case is presented to demonstrate the improved care experience for both patients and providers and to share our learnings more broadly. The…
During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…
In case you missed it, on Nov. 20, the Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…
From pain management to arthroplasty, African American patients with OA and RA experience worse outcomes than white patients. But the reasons for these health disparities are difficult to parse from socioeconomic and cultural factors.
Pandemic fatigue is affecting rheumatologists and their patients in different ways, says Nilanjana Bose, MD, MBA. But efforts are being made at her clinic to stay positive and ensure quality patient care.
Our hospitals have had their finest hour in the care of acutely ill inpatients during the COVID-19 pandemic, including dealing with allocation decisions fairly and transparently, maximizing good outcomes and remaining cognizant of the enduring ethics of healthcare. The honorable traditions of self-effacing conduct and acceptance of some level of personal risk by healthcare professionals…
As of Oct. 1, UnitedHealthcare (UHC) requires that patients fail to respond to both FDA-approved rituximab biosimilars prior to receiving approval for rituximab. Exception: Rituximab-pvvr (Ruxience) is not FDA approved for rheumatoid arthritis.
The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis.
An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.